WO2007056049A3 - Profilage moleculaire de cancer - Google Patents

Profilage moleculaire de cancer Download PDF

Info

Publication number
WO2007056049A3
WO2007056049A3 PCT/US2006/042784 US2006042784W WO2007056049A3 WO 2007056049 A3 WO2007056049 A3 WO 2007056049A3 US 2006042784 W US2006042784 W US 2006042784W WO 2007056049 A3 WO2007056049 A3 WO 2007056049A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
molecular profiling
present
cancer markers
prostate
Prior art date
Application number
PCT/US2006/042784
Other languages
English (en)
Other versions
WO2007056049A2 (fr
Inventor
Arul Chinnaiyan
Sooryanarayana Lnu
Original Assignee
Univ Michigan
Arul Chinnaiyan
Sooryanarayana Lnu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan, Arul Chinnaiyan, Sooryanarayana Lnu filed Critical Univ Michigan
Priority to CA002628390A priority Critical patent/CA2628390A1/fr
Priority to EP06836805A priority patent/EP1945817A4/fr
Publication of WO2007056049A2 publication Critical patent/WO2007056049A2/fr
Publication of WO2007056049A3 publication Critical patent/WO2007056049A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour le diagnostic du cancer, comprenant sans y être limités, des marqueurs de cancer, en particulier, la présente invention concerne des marqueurs de cancer utiles dans le diagnostic et la caractérisation de cancers de la prostate et du sein.
PCT/US2006/042784 2005-11-02 2006-11-02 Profilage moleculaire de cancer WO2007056049A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002628390A CA2628390A1 (fr) 2005-11-02 2006-11-02 Profilage moleculaire de cancer
EP06836805A EP1945817A4 (fr) 2005-11-02 2006-11-02 Profilage moleculaire de cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73285905P 2005-11-02 2005-11-02
US60/732,859 2005-11-02

Publications (2)

Publication Number Publication Date
WO2007056049A2 WO2007056049A2 (fr) 2007-05-18
WO2007056049A3 true WO2007056049A3 (fr) 2008-01-31

Family

ID=38023798

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/042784 WO2007056049A2 (fr) 2005-11-02 2006-11-02 Profilage moleculaire de cancer

Country Status (3)

Country Link
EP (1) EP1945817A4 (fr)
CA (1) CA2628390A1 (fr)
WO (1) WO2007056049A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273539B2 (en) 2006-09-25 2012-09-25 Mayo Foundation For Medical Education And Research Extracellular and membrane-associated prostate cancer markers
US8338109B2 (en) 2006-11-02 2012-12-25 Mayo Foundation For Medical Education And Research Predicting cancer outcome
EP2806054A1 (fr) 2008-05-28 2014-11-26 Genomedx Biosciences Inc. Systèmes et procédés de discrimination basés sur l'expression d'états pathologiques cliniques distincts dans le cancer de la prostate
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
CN102272324A (zh) * 2008-10-01 2011-12-07 诺维奥根迪克斯研究有限公司 前列腺癌分子标记
EP2243843A1 (fr) * 2009-04-24 2010-10-27 Institut Curie HP1ALPHA en tant que marqueur de pronostic dans le cancer humain
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
DK3435084T3 (da) 2012-08-16 2023-05-30 Mayo Found Medical Education & Res Prostatakræftprognose under anvendelse af biomarkører
EP3504348B1 (fr) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Utilisation de signatures génomiques en vue d'une prédiction de la réactivité de patients atteints d'un cancer de la prostate à une radiothérapie postopératoire
US11208697B2 (en) 2017-01-20 2021-12-28 Decipher Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
WO2018167312A1 (fr) * 2017-03-16 2018-09-20 Université Libre de Bruxelles Détection, quantification et/ou isolement de cellules tumorales circulantes sur la base de l'expression du marqueur cd321
WO2018205035A1 (fr) 2017-05-12 2018-11-15 Genomedx Biosciences, Inc Signatures génétiques pour prédire une métastase du cancer de la prostate et identifier la virulence d'une tumeur
CN115436636A (zh) * 2022-11-08 2022-12-06 济南市中心医院 连接粘附分子样蛋白jaml在结直肠癌中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086406A1 (en) * 1998-04-09 2002-07-04 Incyte Pharmaceuticals, Inc. Human ubiquitin-conjugating enzyme homologs
WO2002061081A1 (fr) * 2001-01-31 2002-08-08 Bionomics Limited Une nouvelle cartographie du gene bn01 au chromosome 16q24.3
WO2003088910A2 (fr) * 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Procedes de criblage de modulateurs du cycle cellulaire
WO2005047321A2 (fr) * 2003-11-14 2005-05-26 Creighton University Polynucléotides inhibant l'expression de polypeptides et leurs méthodes d'utilisation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086406A1 (en) * 1998-04-09 2002-07-04 Incyte Pharmaceuticals, Inc. Human ubiquitin-conjugating enzyme homologs
WO2002061081A1 (fr) * 2001-01-31 2002-08-08 Bionomics Limited Une nouvelle cartographie du gene bn01 au chromosome 16q24.3
WO2003088910A2 (fr) * 2002-04-15 2003-10-30 Rigel Pharmaceuticals, Inc. Procedes de criblage de modulateurs du cycle cellulaire
WO2005047321A2 (fr) * 2003-11-14 2005-05-26 Creighton University Polynucléotides inhibant l'expression de polypeptides et leurs méthodes d'utilisation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BEN-IZHAK O. ET AL.: "Inverse Relationship Between SKP2 Ubiquitin Ligase and The Cyclin Dependent Kinase Inhibitor p27Kip1 In Prostate Cancer", THE JOURNAL OF UROLOGY, vol. 170, no. 1, July 2003 (2003-07-01), pages 241 - 245, XP005536043 *
CARDOZO T. ET AL.: "The SCF ubiquitin ligase: insights into a molecular machine", NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 5, no. 9, September 2004 (2004-09-01), pages 739 - 751, XP008127053 *
LU L. ET AL.: "The F-box Protein SKP 2 Mediates Androgen Control of p27 Stability in LNCaP Human Prostate Cancer Cells", BMC CELL BIOLOGY, vol. 3, no. 22, 20 August 2002 (2002-08-20), XP021014065 *
MYERS E.L. ET AL.: "Tsg101, an Inactive Homologue of Ubiquitin Ligase E2, Interacts Specifically with Human Immunodeficiency Virus Type 2 Gag Polyprotein and Results in Increased Levels of Ubiquitinated Gag", JOURNAL OF VIROLOGY, vol. 76, no. 22, November 2002 (2002-11-01), pages 11226 - 11235, XP002968048 *
See also references of EP1945817A4 *
STUBBS A.P. ET AL.: "Differentially Expressed Genes in Hormone Refractory Prostate Cancer", AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 5, May 1999 (1999-05-01), pages 1335 - 1343, XP001176972 *

Also Published As

Publication number Publication date
EP1945817A2 (fr) 2008-07-23
WO2007056049A2 (fr) 2007-05-18
CA2628390A1 (fr) 2007-05-18
EP1945817A4 (fr) 2008-12-10

Similar Documents

Publication Publication Date Title
WO2007056049A3 (fr) Profilage moleculaire de cancer
WO2005123993A8 (fr) Profilage micromatriciel bactériophage de la réponse humorale à la maladie
WO2006012646A3 (fr) Marqueurs de cancers amacr
WO2007053648A3 (fr) Compositions et méthodes pour traiter et diagnostiquer un cancer
WO2007009755A8 (fr) Compositions et methodes de diagnostic du cancer contenant des marqueurs pantumoraux
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007081740A3 (fr) Méthodes et compositions basés sur des micro-arn et s'appliquant au diagnostic et au traitement de cancers solides
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
WO2006119365A3 (fr) Compositions et procedes destines au diagnostic et au traitement du cancer
WO2009108860A3 (fr) Procédés et compositions à base de micro-arn permettant de diagnostiquer, de pronostiquer et de traiter des troubles liés à la prostate
WO2009036427A3 (fr) Biomarqueurs du cancer de la prostate
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
WO2008094708A3 (fr) Antagonistes de l'activine-actriia et leurs utilisations dans le traitement ou la prévention du cancer du sein
WO2006095086A8 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
HK1179275A1 (en) Compositions and methods for diagnosing and treating cancer
WO2008061020A3 (fr) Méthodes permettant de traiter, de diagnostiquer ou de détecter un cancer
WO2007120787A3 (fr) Procede de traitement, de diagnostic ou de detection du cancer
WO2007100920A3 (fr) Diagnostic et traitement du cancer de la prostate
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
WO2008115750A3 (fr) Compositions et procédés pour le traitement du cancer
WO2006086772A3 (fr) Procede de diagnostic et de traitement du cancer au moyen de variants d'epissure de $g(b)-catenine
WO2009003082A3 (fr) Compositions immunologiques utilisées en tant que biomarqueurs et/ou agents thérapeutiques pour le cancer
WO2008092002A3 (fr) Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
WO2009105457A3 (fr) Marqueurs du cancer slit2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2628390

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006836805

Country of ref document: EP